Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...

Already, significant harm has been done to inhibit progress combating HIV/AIDS, and the next four years could return us to ...

Babies born to mothers with HIV can escape infection only if the woman was properly treated during pregnancy or the infant is treated immediately after birth. If the drugs are not taken, a body is ...

The goal of brushing one’s teeth is to have fresh breath and prevent cavities. But the effect of toothpaste on the complex ...

HIV/AIDS continues to disproportionately affect Black Americans, despite overall progress in reducing infection rates.

The FDA has accepted Gilead Sciences’ new drug application for lenacapavir as a long-lasting injectable to prevent HIV infection and set a date of June 19 to decide on its approval, Gilead ...

The company is planning a Phase 3 trial for the new formulation of lenacapavir, Stat reports. Other pharma and technology news is on microplastics and the spread of antibiotic-resistant superbugs; a ...